Utthara Nayar, Ph.D.

2011 Weill Cornell Medical College, New York, NY, United States 
Cell Biology, Virology Biology
"Utthara Nayar"


Sign in to add mentor
Ethel Cesarman grad student 2011 Weill Cornell Medical College
 (Identification of novel cellular and viral inhibitors in gammaherpesvirus-associated malignancies.)
Nikhil Wagle post-doc 2015-2020 Harvard Medical School, Dana Farber Cancer Institute, Broad Institute of Harvard and MIT,
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Brett JO, Dubash TD, Johnson GN, et al. (2023) A Gene Panel Associated With Abemaciclib Utility in -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. Jco Precision Oncology. 7: e2200532
Qi M, Nayar U, Ludwig LS, et al. (2021) cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries. Bmc Bioinformatics. 22: 611
Mao P, Cohen O, Kowalski KJ, et al. (2020) Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Wander SA, Cohen O, Gong X, et al. (2020) The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery
Persky NS, Hernandez D, Do Carmo M, et al. (2020) Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nature Structural & Molecular Biology. 27: 92-104
Nayar U, Cohen O, Kapstad C, et al. (2018) Acquired HER2 mutations in ER metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature Genetics
Wander SA, Cohen O, Johnson GN, et al. (2018) Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Journal of Clinical Oncology. 36: 12016-12016
Nayar U, Sadek J, Reichel J, et al. (2017) Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. The Journal of Clinical Investigation
Nayar U, Sadek J, Reichel JB, et al. (2015) Exquisite Sensitivity of Plasma Cell Malignancies to a Novel Nucleoside Analog Is Mediated By Overexpressed Adenosine Kinase Blood. 126: 1812-1812
Nayar U, Reichel J, Sadek J, et al. (2015) Abstract 4496: Genomics-based resistome analysis revealed endogenous adenosine kinase levels as a chief determinant of specificity for a novel nucleoside analog lymphoma inhibitor Cancer Research. 75: 4496-4496
See more...